Literature DB >> 11020650

Galactose metabolism and ovarian toxicity.

G Liu1, G E Hale, C L Hughes.   

Abstract

Galactose is an energy-providing nutrient and also a necessary basic substrate for the biosynthesis of many macromolecules in the body. Metabolic pathways for galactose are important not only for the provision of these pathways but also for the prevention of galactose and galactose metabolite accumulation. Problems with galactose metabolism can cause a variety of clinical manifestations in animals and humans. It has been found that the mammalian ovary is particularly susceptible to damage from the accumulation of galactose and galactose metabolites. The galactose metabolites Gal-1-P, galactitol, and UDPgal are all considered to be important in this toxicity and proposed mechanisms include interference with ovarian apoptosis and gonadotrophin signaling. This review addresses the most recent scientific findings regarding the possible mechanisms of galactose-induced ovarian toxicity and also the possible protective role of hormonal and antioxidant therapy. In addition, the available epidemiologic and scientific evidence linking galactose intake with risk of ovarian cancer is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020650     DOI: 10.1016/s0890-6238(00)00096-4

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  19 in total

1.  Cross-sectional analysis of speech and cognitive performance in 32 patients with classic galactosemia.

Authors:  Björn Hoffmann; Udo Wendel; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

Review 2.  Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities.

Authors:  Mili Thakur; Gerald Feldman; Elizabeth E Puscheck
Journal:  J Assist Reprod Genet       Date:  2017-09-20       Impact factor: 3.412

3.  Ginsenoside Rg1 improves fertility and reduces ovarian pathological damages in premature ovarian failure model of mice.

Authors:  Lianli He; Li Ling; Tianqin Wei; Yaping Wang; Zhengai Xiong
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

4.  Dairy Consumption and Total Cancer and Cancer-Specific Mortality: A Meta-Analysis of Prospective Cohort Studies.

Authors:  Shaoyue Jin; Youjin Je
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

5.  Prolactin signaling through the short form of its receptor represses forkhead transcription factor FOXO3 and its target gene galt causing a severe ovarian defect.

Authors:  Julia Halperin; Y Sangeeta Devi; Sangeeta Y Devi; Shai Elizur; Carlos Stocco; Aurora Shehu; Diane Rebourcet; Terry G Unterman; Nancy D Leslie; Jamie Le; Nadine Binart; Geula Gibori
Journal:  Mol Endocrinol       Date:  2007-11-01

Review 6.  Galactose toxicity in animals.

Authors:  Kent Lai; Louis J Elsas; Klaas J Wierenga
Journal:  IUBMB Life       Date:  2009-11       Impact factor: 3.885

7.  Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.

Authors:  Xingchen Shang; Xia Zhong; Xingsong Tian
Journal:  Tumour Biol       Date:  2016-03-02

Review 8.  The mitochondrial landscape of ovarian cancer: emerging insights.

Authors:  Pallavi Shukla; Keshav K Singh
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

Review 9.  Ovarian function in girls and women with GALT-deficiency galactosemia.

Authors:  Judith L Fridovich-Keil; Cynthia S Gubbels; Jessica B Spencer; Rebecca D Sanders; Jolande A Land; Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

10.  Prolactin signaling through the short isoform of the mouse prolactin receptor regulates DNA binding of specific transcription factors, often with opposite effects in different reproductive issues.

Authors:  Y Sangeeta Devi; Aurora Shehu; Julia Halperin; Carlos Stocco; Jamie Le; Anita M Seibold; Geula Gibori
Journal:  Reprod Biol Endocrinol       Date:  2009-08-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.